Michael Matson
Stock Analyst at Needham
(4.17)
# 1,528
Out of 4,534 analysts
1567
Total ratings
48.5%
Success rate
5.7%
Average return
Main Sectors:
Stocks Rated by Michael Matson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AORT Artivion | Reiterated: Buy | $44 | $25.14 | +75.02% | 60 | Jul 20, 2026 | |
| PSNL Personalis | Downgraded: Hold | n/a | $13.24 | - | 39 | Jul 20, 2026 | |
| ATRC AtriCure | Initiated Coverage: Buy | $45 | $34.90 | +28.94% | 102 | Jul 13, 2026 | |
| CNMD CONMED | Maintained: Hold | n/a | $43.78 | - | 82 | Jul 13, 2026 | |
| INMD InMode | Maintained: Hold | n/a | $15.52 | - | 41 | Jul 13, 2026 | |
| BSX Boston Scientific | Rated: Buy | $77 → $57 | $44.18 | +29.02% | 127 | Jul 8, 2026 | |
| RMD ResMed | Maintained: Hold | n/a | $197.26 | - | 95 | Jul 8, 2026 | |
| MDT Medtronic | Reiterated: Buy | $101 | $83.89 | +20.40% | 97 | Jun 17, 2026 | |
| TMDX TransMedics Group | Maintained: Buy | $142 | $73.36 | +93.57% | 28 | Jun 9, 2026 | |
| VCYT Veracyte | Reiterated: Buy | $48 → $57 | $57.69 | -1.20% | 35 | Jun 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $165 | $157.35 | +4.86% | 13 | May 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52 | $27.27 | +90.69% | 17 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $4.79 | +87.89% | 35 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $0.9178 | +226.87% | 32 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $216.31 | - | 33 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $6.32 | +89.87% | 86 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $79.41 | - | 46 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $147 | $134.96 | +8.92% | 69 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $81 | $80.55 | +0.56% | 86 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $86 | $93.61 | -8.13% | 10 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $101 → $90 | $75.32 | +19.49% | 68 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $454 → $418 | $321.78 | +29.90% | 73 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $19.41 | +54.56% | 51 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $14.26 | +5.19% | 38 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $89.93 | - | 88 | Apr 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $318.47 | - | 24 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.035 | n/a | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $65 → $82 | $77.28 | n/a | 22 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $27 | $17.18 | n/a | 1 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.28 | n/a | 50 | Dec 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $1.56 | n/a | 10 | Nov 11, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1 | $8.67 | n/a | 1 | Nov 6, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $636 | $350.52 | n/a | 1 | Apr 19, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $15 → $14 | $6.89 | n/a | 4 | Apr 9, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $11.58 | n/a | 1 | Apr 17, 2009 |
Artivion
Jul 20, 2026
Reiterated: Buy
Price Target: $44
Current: $25.14
Upside: +75.02%
Personalis
Jul 20, 2026
Downgraded: Hold
Price Target: n/a
Current: $13.24
Upside: -
AtriCure
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $34.90
Upside: +28.94%
CONMED
Jul 13, 2026
Maintained: Hold
Price Target: n/a
Current: $43.78
Upside: -
InMode
Jul 13, 2026
Maintained: Hold
Price Target: n/a
Current: $15.52
Upside: -
Boston Scientific
Jul 8, 2026
Rated: Buy
Price Target: $77 → $57
Current: $44.18
Upside: +29.02%
ResMed
Jul 8, 2026
Maintained: Hold
Price Target: n/a
Current: $197.26
Upside: -
Medtronic
Jun 17, 2026
Reiterated: Buy
Price Target: $101
Current: $83.89
Upside: +20.40%
TransMedics Group
Jun 9, 2026
Maintained: Buy
Price Target: $142
Current: $73.36
Upside: +93.57%
Veracyte
Jun 1, 2026
Reiterated: Buy
Price Target: $48 → $57
Current: $57.69
Upside: -1.20%
May 27, 2026
Upgraded: Buy
Price Target: $165
Current: $157.35
Upside: +4.86%
May 18, 2026
Maintained: Buy
Price Target: $52
Current: $27.27
Upside: +90.69%
May 14, 2026
Maintained: Buy
Price Target: $9
Current: $4.79
Upside: +87.89%
May 14, 2026
Reiterated: Buy
Price Target: $3
Current: $0.9178
Upside: +226.87%
May 12, 2026
Maintained: Hold
Price Target: n/a
Current: $216.31
Upside: -
May 8, 2026
Maintained: Buy
Price Target: $12
Current: $6.32
Upside: +89.87%
May 7, 2026
Maintained: Hold
Price Target: n/a
Current: $79.41
Upside: -
May 7, 2026
Maintained: Buy
Price Target: $147
Current: $134.96
Upside: +8.92%
May 6, 2026
Reiterated: Buy
Price Target: $81
Current: $80.55
Upside: +0.56%
May 6, 2026
Reiterated: Buy
Price Target: $86
Current: $93.61
Upside: -8.13%
May 1, 2026
Maintained: Buy
Price Target: $101 → $90
Current: $75.32
Upside: +19.49%
May 1, 2026
Reiterated: Buy
Price Target: $454 → $418
Current: $321.78
Upside: +29.90%
May 1, 2026
Reiterated: Buy
Price Target: $30
Current: $19.41
Upside: +54.56%
Apr 29, 2026
Maintained: Buy
Price Target: $15
Current: $14.26
Upside: +5.19%
Apr 28, 2026
Maintained: Hold
Price Target: n/a
Current: $89.93
Upside: -
Feb 25, 2026
Maintained: Hold
Price Target: n/a
Current: $318.47
Upside: -
Apr 5, 2024
Downgraded: Hold
Price Target: n/a
Current: $0.035
Upside: n/a
May 5, 2021
Maintained: Buy
Price Target: $65 → $82
Current: $77.28
Upside: n/a
Mar 18, 2020
Maintained: Buy
Price Target: $27
Current: $17.18
Upside: n/a
Dec 6, 2018
Rated: Hold
Price Target: n/a
Current: $4.28
Upside: n/a
Nov 11, 2016
Maintained: Buy
Price Target: n/a
Current: $1.56
Upside: n/a
Nov 6, 2015
Reiterated: Buy
Price Target: $1
Current: $8.67
Upside: n/a
Apr 19, 2013
Maintained: Buy
Price Target: $636
Current: $350.52
Upside: n/a
Apr 9, 2013
Upgraded: Buy
Price Target: $15 → $14
Current: $6.89
Upside: n/a
Apr 17, 2009
Downgraded: Sell
Price Target: n/a
Current: $11.58
Upside: n/a